Skip to the page

Data / Drug companies / XLCare Pharmaceuticals, Inc.

XLCare Pharmaceuticals, Inc.: 177 products in the FDA NDC directory, labeler code 72865

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

XLCare Pharmaceuticals, Inc. (labeler code 72865) lists 177 products in the FDA National Drug Code Directory, covering 54 finished drugs by generic name. By type: 177 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 9, 2026.

The request: Watch XLCare Pharmaceuticals, Inc. (FDA labeler code 72865): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
72865
Products in commercial distribution
177
Packages
386
Finished drugs by generic name
54
Prescription products
177
Over the counter products
0
Controlled substance products
Schedule II 32, Schedule III 1, Schedule V 1
Flagged as original packager
171 of 171 products that carry the flag
Started marketing in the last 12 months
17
Earliest marketing start
April 11, 2017
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)177100%

Products by type

TypeProductsShare
Prescription drugs177100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet8346.9%
Tablet, film coated5329.9%
Tablet, extended release1810.2%
Capsule147.9%
Tablet, chewable31.7%
Capsule, liquid filled21.1%
Tablet, delayed release21.1%
Injection10.6%
Solution10.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Tofacitinib72865-367Tablet, film coatedGeneric drugs (ANDA)October 9, 2026
Tofacitinib72865-366Tablet, film coatedGeneric drugs (ANDA)October 9, 2026
Simvastatin72865-309Tablet, film coatedGeneric drugs (ANDA)January 21, 2026
Simvastatin72865-308Tablet, film coatedGeneric drugs (ANDA)January 21, 2026
Simvastatin72865-307Tablet, film coatedGeneric drugs (ANDA)January 21, 2026
Simvastatin72865-306Tablet, film coatedGeneric drugs (ANDA)January 21, 2026
Simvastatin72865-305Tablet, film coatedGeneric drugs (ANDA)January 21, 2026
Carbidopa and levodopa72865-363TabletGeneric drugs (ANDA)January 19, 2026
Carbidopa and levodopa72865-362TabletGeneric drugs (ANDA)January 19, 2026
Carbidopa and levodopa72865-361TabletGeneric drugs (ANDA)January 19, 2026
Allopurinol72865-304TabletGeneric drugs (ANDA)January 8, 2026
Allopurinol72865-303TabletGeneric drugs (ANDA)January 8, 2026
Tamsulosin hydrochloride72865-350CapsuleGeneric drugs (ANDA)January 1, 2026
Sodium oxybate72865-349SolutionGeneric drugs (ANDA)January 1, 2026
Rivaroxaban72865-321Tablet, film coatedGeneric drugs (ANDA)December 17, 2025
Meloxicam72865-333TabletGeneric drugs (ANDA)December 12, 2025
Meloxicam72865-332TabletGeneric drugs (ANDA)December 12, 2025
Mirtazapine72865-371Tablet, film coatedGeneric drugs (ANDA)October 2, 2025
Mirtazapine72865-370Tablet, film coatedGeneric drugs (ANDA)October 2, 2025
Mirtazapine72865-369Tablet, film coatedGeneric drugs (ANDA)October 2, 2025
Mirtazapine72865-368Tablet, film coatedGeneric drugs (ANDA)October 2, 2025
Sacubitril and Valsartan72865-312TabletGeneric drugs (ANDA)September 30, 2025
Sacubitril and Valsartan72865-311TabletGeneric drugs (ANDA)September 30, 2025
Sacubitril and Valsartan72865-310TabletGeneric drugs (ANDA)September 30, 2025
Pitavastatin calcium72865-293Tablet, film coatedGeneric drugs (ANDA)September 18, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.